In recent years, the green transformation of the pharmaceutical industry has become a widely discussed topic, with continuous manufacturing emerging as one of the key technologies driving this shift. From the national Opinions on Accelerating the Comprehensive Green Transformation of Economic and Social Development to the implementation of the ICH Q13 guideline, continuous manufacturing has become a key lever in the industry's green transition, thanks to its ability to streamline processes and reduce energy consumption. However, challenges such as domestic equipment localization, process validation, and regulatory alignment remain significant obstacles in its adoption. It closely resembles the rise of biologics years ago: everyone recognized it as the future, yet no one could pinpoint exactly when the turning point would come.
Efficiency Leap Driven by Technological Generation Gaps
If traditional batch production is akin to an old-fashioned train, continuous manufacturing resembles a high-speed rail system - while the former requires frequent stops to load and unload materials, the latter enables uninterrupted, high-speed operation. This generation gap is especially evident in the synthesis of active pharmaceutical ingredients (APIs). In traditional processes, ingredients are repeatedly transferred between separate reactors, with each stage followed by lengthy periods of cooling, sampling, and testing. In contrast, continuous manufacturing enables dynamic flow of ingredients through microreactors, allowing real-time control of reaction temperature, pressure, and flow rate. As a result, production cycles that once took weeks can now be completed within hours. Take the synthesis technology of cardiovascular drugs as an example: after transitioning to continuous manufacturing, the reaction efficiency increased by 30%, and energy costs per kilogram of product dropped by 25%. In today's environment of routine price-cutting through centralized procurement, such gains in efficiency are especially valuable.
Policy momentum has further fueled industry enthusiasm. In 2023, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) issued the Technical Guidelines for Continuous Manufacturing of Chemical Oral Solid Preparation, providing a clear regulatory pathway for the implementation of this technology. Innovative local government initiatives have also set examples for continuous manufacturing. In Shenzhen, the "industrial upscaling" model places production equipment vertically within multi-story factory buildings, optimizing the physical space for continuous manufacturing through a three-dimensional layout. This approach - pursuing efficiency by building upward - is now rapidly being replicated in land-constrained regions such as the Yangtze River Delta and the Pearl River Delta.
Low localization rates of equipment, complex process validation, and lengthy regulatory approval cycles - how can the industry tackle these tough challenges?
While the industry envisions a promising future for continuous manufacturing, engineers on the ground are grappling with real-world obstacles. Step into any pharmaceutical company undergoing transformation, and you'll likely hear similar complaints: "An imported reactor costs as much as an apartment, but we don't dare to use equipment made in China on our main production lines." Currently, the localization rate of core equipment such as microreactors and continuous chromatography systems remains below 30%, with multinational companies like Corning and Sartorius continuing to dominate the high-end market. This dilemma is not solely about technological gaps. For example, a Chinese equipment manufacturer may have developed microreactors with precision that meets international standards. Yet pharmaceutical companies are still willing to pay three times the price for imported equipment - just to avoid potential risks during process validation. This trust deficit is proving more difficult to overcome than the technical shortcomings themselves.
The restructuring of quality control systems represents another quiet revolution. Traditional batch production relies on end-product testing - akin to a final exam where everything hinges on one test. In contrast, contin...
(All Rights Reserved)